Loading...

MEDICAMEQ Medicamen Biotech Ltd Expansion Plans Announcement

Mdcm

MDCM

Medicamen Biotech Ltd

(MEDICAMEQ)

2025 Announcement

Show Summary

Show Summary

Financial Results Published

Annual Compliance Filed

Correction Notice

Board Meeting Outcome

Securities Allotment

SEBI Compliance Certification

Share Acquisition Update

Distribution Agreement

New Contract Signed

Market Expansion

Share Purchase Intimation

Market Expansion

Extra-Ordinary Meeting

Top Supplier Award

Equity Share Issue

Price Movement Clarification

Manufacturing Agreement

Financial Results Released

Management Change

Compliance Certification

RTA Name Change

Price Movement Clarification

Newspaper Publication

Financial Results Published

SEBI Compliance

Investor Meeting

Insider Trading Notice

EU GMP Certification

AGM Notice Publication

Financial Results Published

Resignation of CFO

Certificate Submission

Completed Inspection

Financial Results Publication

Secretarial Compliance Report

Deviation in Utilization of...

FDA Inspection Completion

Certificate Submission

Compliance Certificate

Certification Submission

Insider Trading Disclosure

FDA Audit in Ethiopia

Acquisition Disclosure

Acquisition Disclosure

Investment Disclosure

Equity Sale Disclosure

Insider Trading Disclosure

Insider Trading Disclosure

Insider Trading Disclosure

Financial Results Publication

Certificate Confirmation

Financial Results Published

Clarification on Price Move...

Certificate under Regulatio...

Financial Statements

Certificate under Regulatio...

First ANDA filing

Asset Sale/Management Chang...

Publication of Results

External Links:

Data:

Medicamen Biotech Ltd has signed a Distribution Agreement with XGX Pharma, Denmark for three products, including two oncology products and one Beta-lactam product, with marketing authorization held by Medicamen as of April 8, 2025.

AI Assistant

Medicamen Biotech Ltd

2025

Announcement

Find Answers

Ask about any part of the document to get insights, explanations, or key details.